Palatin Technologies

Palatin Technologies is a biopharmaceutical company based in Cranbury, New Jersey. The company has 51 employees and generates $50 million in annual revenue. Palatin (NYSE American: PTN) is a biopharmaceutical company developing medications that target the melanocortin peptide receptor system. This system plays a role in regulating important bodily functions like appetite, energy levels, sexual desire, and the reduction of inflammation. Palatin is focused on developing therapeutics that leverage the melanocortin system to treat a range of conditions, including eye diseases, gastrointestinal issues, and kidney disease. Their most advanced product, PL9643, is a topical treatment for dry eye disease and is slated to begin Phase 3 clinical trials in the second half of 2021. The company's portfolio also includes therapeutics for other ophthalmic conditions like uveitis, retinopathies, and corneal diseases. Palatin is also exploring the potential of melanocortin-based therapies for ulcerative colitis and kidney disease. Their flagship product, Vyleesi®, is the first and only on-demand, FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. To learn more about Palatin Technologies and its product pipeline, visit www.palatin.com. For information on Vyleesi®, including Important Safety Information, please visit www.vyleesi.com/.